Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

John Gallacher; Frederic de Reydet de Vulpillieres; Billy Amzal; Zuzanna Angehrn; Christin Bexelius; Christophe Bintener; Jacoline C. Bouvy; Laura Campo; Carlos Diaz; Jean Georges; Alastair Gray; Antje Hottgenroth; Pall Jonsson; Brent Mittelstadt; Michele H. Potashman; Catherine Reed; Cathie Sudlow; Robin Thompson; Antje Tockhorn-Heidenreich; Andrew Turner; Johan van der Lei; Pieter Jelle Visser; ROADMAP consortium

doi:10.3233/JAD-180370

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

John Gallacher^*, Frederic de Reydet de Vulpillieres, Billy Amzal, Zuzanna Angehrn, Christin Bexelius, Christophe Bintener, Jacoline C. Bouvy, Laura Campo, Carlos Diaz, Jean Georges, Alastair Gray, Antje Hottgenroth, Pall Jonsson, Brent Mittelstadt, Michele H. Potashman, Catherine Reed, Cathie Sudlow, Robin Thompson, Antje Tockhorn-Heidenreich, Andrew TurnerJohan van der Lei, Pieter Jelle Visser, ROADMAP consortium

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

19 Citations (Web of Science)

Abstract

ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

Original language	English
Pages (from-to)	495-501
Number of pages	7
Journal	Journal of Alzheimer's Disease
Volume	67
Issue number	2
DOIs	https://doi.org/10.3233/JAD-180370
Publication status	Published - 2019

Keywords

Alzheimer's disease
data sharing
data systems
health policy
patient outcome assessment
real-world clinical trials
systems integration
FRAMEWORK
DEMENTIA
TRIALS

Access to Document

10.3233/JAD-180370

Cite this

Gallacher, J., de Vulpillieres, F. D. R., Amzal, B., Angehrn, Z., Bexelius, C., Bintener, C., Bouvy, J. C., Campo, L., Diaz, C., Georges, J., Gray, A., Hottgenroth, A., Jonsson, P., Mittelstadt, B., Potashman, M. H., Reed, C., Sudlow, C., Thompson, R., Tockhorn-Heidenreich, A., ... ROADMAP consortium (2019). Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project. Journal of Alzheimer's Disease, 67(2), 495-501. https://doi.org/10.3233/JAD-180370

@article{6a8f9e264a5947978845bf5f3c2950af,

title = "Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project",

abstract = "ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.",

keywords = "Alzheimer's disease, data sharing, data systems, health policy, patient outcome assessment, real-world clinical trials, systems integration, FRAMEWORK, DEMENTIA, TRIALS",

author = "John Gallacher and {de Vulpillieres}, {Frederic de Reydet} and Billy Amzal and Zuzanna Angehrn and Christin Bexelius and Christophe Bintener and Bouvy, {Jacoline C.} and Laura Campo and Carlos Diaz and Jean Georges and Alastair Gray and Antje Hottgenroth and Pall Jonsson and Brent Mittelstadt and Potashman, {Michele H.} and Catherine Reed and Cathie Sudlow and Robin Thompson and Antje Tockhorn-Heidenreich and Andrew Turner and {van der Lei}, Johan and Visser, {Pieter Jelle} and {ROADMAP consortium}",

year = "2019",

doi = "10.3233/JAD-180370",

language = "English",

volume = "67",

pages = "495--501",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "IOS Press",

number = "2",

}

Gallacher, J, de Vulpillieres, FDR, Amzal, B, Angehrn, Z, Bexelius, C, Bintener, C, Bouvy, JC, Campo, L, Diaz, C, Georges, J, Gray, A, Hottgenroth, A, Jonsson, P, Mittelstadt, B, Potashman, MH, Reed, C, Sudlow, C, Thompson, R, Tockhorn-Heidenreich, A, Turner, A, van der Lei, J, Visser, PJ & ROADMAP consortium 2019, 'Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project', Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 495-501. https://doi.org/10.3233/JAD-180370

TY - JOUR

T1 - Challenges for Optimizing Real-World Evidence in Alzheimer's Disease

T2 - The ROADMAP Project

AU - Gallacher, John

AU - de Vulpillieres, Frederic de Reydet

AU - Amzal, Billy

AU - Angehrn, Zuzanna

AU - Bexelius, Christin

AU - Bintener, Christophe

AU - Bouvy, Jacoline C.

AU - Campo, Laura

AU - Diaz, Carlos

AU - Georges, Jean

AU - Gray, Alastair

AU - Hottgenroth, Antje

AU - Jonsson, Pall

AU - Mittelstadt, Brent

AU - Potashman, Michele H.

AU - Reed, Catherine

AU - Sudlow, Cathie

AU - Thompson, Robin

AU - Tockhorn-Heidenreich, Antje

AU - Turner, Andrew

AU - van der Lei, Johan

AU - Visser, Pieter Jelle

AU - ROADMAP consortium

PY - 2019

Y1 - 2019

N2 - ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

AB - ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

KW - Alzheimer's disease

KW - data sharing

KW - data systems

KW - health policy

KW - patient outcome assessment

KW - real-world clinical trials

KW - systems integration

KW - FRAMEWORK

KW - DEMENTIA

KW - TRIALS

U2 - 10.3233/JAD-180370

DO - 10.3233/JAD-180370

M3 - Editorial

C2 - 30584137

SN - 1387-2877

VL - 67

SP - 495

EP - 501

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 2

ER -